Soligenix Publishes Summary of HyBryte™ Clinical Trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SNGX?
Source: PRnewswire
- Clinical Trial Results: Soligenix's summary of HyBryte™ clinical trials reveals significant efficacy in treating cutaneous T-cell lymphoma (CTCL), with 16% of patients achieving at least a 50% reduction in lesions at 8 weeks in the first phase study, compared to only 4% in the placebo group (p=0.04), laying a solid foundation for future market introduction.
- Safety Advantages: HyBryte™ utilizes a non-mutagenic mechanism and a safe visible light source, demonstrating better tolerability compared to traditional treatments like mechlorethamine, and showing excellent efficacy in treating thicker plaque lesions and difficult-to-treat variants, potentially positioning it as a first-line treatment option for CTCL patients.
- Future Research Plans: The ongoing FLASH2 Phase 3 study is expected to complete its interim analysis in Q2 2026, aiming to further validate the efficacy and safety of HyBryte™, and if successful, will support FDA and EMA marketing approvals, accelerating the product's commercialization process.
- Market Potential: With approximately 69,000 CTCL patients in the U.S. and Europe and about 7,000 new cases annually, the successful development of HyBryte™ could not only meet this unmet medical need but also generate substantial market revenue for Soligenix.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNGX
Wall Street analysts forecast SNGX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.260
Low
10.00
Averages
10.00
High
10.00
Current: 1.260
Low
10.00
Averages
10.00
High
10.00
About SNGX
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soligenix Publishes Summary of HyBryte™ Clinical Trials for CTCL
- Clinical Trial Results: Soligenix announced that a summary of its HyBryte™ (synthetic hypericin) clinical trials for treating cutaneous T-cell lymphoma (CTCL) has been published in Expert Opinion on Investigational Drugs, highlighting its potential as a new first-line treatment option for early-stage CTCL.
- Significant Efficacy Data: In the first phase of the clinical trial, 16% of patients receiving HyBryte™ achieved at least a 50% reduction in lesions at 8 weeks, compared to only 4% in the placebo group, indicating a significant advantage in improving CTCL patient outcomes.
- Safety and Tolerability: HyBryte™ demonstrated good safety and tolerability, particularly when compared to traditional therapies, as its non-mutagenic mechanism and non-carcinogenic light source make it a safer alternative, reducing the risk of side effects for patients.
- Future Research Directions: Soligenix plans to complete an interim analysis of the FLASH2 study in Q2 2026, which will further validate the efficacy of HyBryte™, with expectations to accelerate patient recruitment and drive the drug's market approval process.
See More
Soligenix Publishes Summary of HyBryte™ Clinical Trials
- Clinical Trial Results: Soligenix's summary of HyBryte™ clinical trials reveals significant efficacy in treating cutaneous T-cell lymphoma (CTCL), with 16% of patients achieving at least a 50% reduction in lesions at 8 weeks in the first phase study, compared to only 4% in the placebo group (p=0.04), laying a solid foundation for future market introduction.
- Safety Advantages: HyBryte™ utilizes a non-mutagenic mechanism and a safe visible light source, demonstrating better tolerability compared to traditional treatments like mechlorethamine, and showing excellent efficacy in treating thicker plaque lesions and difficult-to-treat variants, potentially positioning it as a first-line treatment option for CTCL patients.
- Future Research Plans: The ongoing FLASH2 Phase 3 study is expected to complete its interim analysis in Q2 2026, aiming to further validate the efficacy and safety of HyBryte™, and if successful, will support FDA and EMA marketing approvals, accelerating the product's commercialization process.
- Market Potential: With approximately 69,000 CTCL patients in the U.S. and Europe and about 7,000 new cases annually, the successful development of HyBryte™ could not only meet this unmet medical need but also generate substantial market revenue for Soligenix.
See More
Soligenix Receives PIM Designation for SGX945 in the UK
- PIM Designation Achieved: Soligenix's SGX945 (dusquetide) has received Promising Innovative Medicine (PIM) designation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA), marking a significant advancement in its treatment for Behçet's Disease and potentially accelerating access through the Early Access to Medicines Scheme (EAMS).
- Clinical Data Validation: The MHRA's recognition of dusquetide's compliance with PIM criteria is based on Phase 2 clinical trial data, indicating its potential to provide earlier treatment options for patients, thereby improving their quality of life and addressing unmet medical needs.
- Significant Efficacy: SGX945 demonstrated a 40% improvement compared to placebo after four weeks of treatment, surpassing apremilast's 37% improvement, highlighting its competitive edge in clinical applications and likely attracting increased investor interest.
- Strong IP Position: Soligenix holds robust intellectual property rights in its IDR technology platform, including patents for the composition of dusquetide, which provides legal protection for future market commercialization and enhances the company's competitiveness in the biopharmaceutical sector.
See More
Soligenix Receives UK PIM Designation for SGX945
- PIM Designation Achieved: Soligenix's SGX945 (dusquetide) has received Promising Innovative Medicine (PIM) designation from the UK's MHRA, marking a significant advancement in treating Behçet's Disease and providing patients with earlier access to groundbreaking therapies.
- Clinical Data Support: Based on Phase 2 clinical data, dusquetide is expected to offer significant advantages in treating Behçet's Disease, potentially improving patients' quality of life and alleviating symptoms effectively.
- Substantial Market Potential: With over 1 million patients worldwide suffering from Behçet's Disease, the successful commercialization of SGX945 could fill a critical market gap, addressing the urgent need for effective treatments and potentially generating significant revenue.
- Safety Validation: In a Phase 1 study involving 84 healthy volunteers, SGX945 demonstrated excellent safety and tolerability, with significantly reduced side effects compared to existing treatments, thereby enhancing its competitive position in the market.
See More
Soligenix Receives Positive EMA Orphan Drug Recommendation
- Orphan Drug Qualification: Soligenix announced that its SGX945 (active ingredient dusquetide) received a positive recommendation from the EMA Committee for Orphan Medicinal Products, marking a significant advancement in treating Behçet's Disease and expected to provide a 10-year marketing exclusivity period, enhancing its competitive edge in the rare disease sector.
- Clinical Trial Results: In the Phase 2a clinical trial, SGX945 demonstrated biological efficacy and safety in 8 patients with Behçet's Disease, showing a 40% improvement over the placebo group within 4 weeks, laying a solid foundation for future market approval.
- Significant Market Demand: With approximately 1 million people affected by Behçet's Disease globally, particularly in Turkey and Europe, SGX945 presents substantial market potential to address unmet medical needs, potentially leading to significant revenue growth for the company.
- Intellectual Property Advantage: Soligenix holds a strong intellectual property position in its IDR technology platform, including patents for the composition of dusquetide, which will provide crucial legal protection and competitive advantages in future product development and market commercialization.
See More
Soligenix Receives Positive EMA Orphan Drug Recommendation
- Orphan Drug Qualification: Soligenix announced that its SGX945 (active ingredient dusquetide) received a positive recommendation from the EMA's Committee for Orphan Medicinal Products, marking a significant advancement in the treatment of Behçet's Disease and expected to provide a 10-year market exclusivity period.
- Clinical Trial Results: In the Phase 2a clinical trial, SGX945 demonstrated biological efficacy and safety in 8 patients with Behçet's Disease, showing a 40% improvement compared to the placebo group after 4 weeks, laying the groundwork for future market approval.
- Significant Market Demand: With approximately 1 million people affected by Behçet's Disease globally, particularly in Turkey and Europe, the urgent need for effective treatments highlights the potential market impact of SGX945, significantly enhancing Soligenix's position in the biopharmaceutical sector.
- Intellectual Property Protection: Soligenix holds a strong intellectual property position in its IDR technology platform, including patents for the composition of dusquetide, which will provide crucial support for the company's future product development and market commercialization efforts.
See More
Soligenix Publishes Summary of HyBryte™ Clinical Trials for CTCL
- Clinical Trial Results: Soligenix announced that a summary of its HyBryte™ (synthetic hypericin) clinical trials for treating cutaneous T-cell lymphoma (CTCL) has been published in Expert Opinion on Investigational Drugs, highlighting its potential as a new first-line treatment option for early-stage CTCL.
- Significant Efficacy Data: In the first phase of the clinical trial, 16% of patients receiving HyBryte™ achieved at least a 50% reduction in lesions at 8 weeks, compared to only 4% in the placebo group, indicating a significant advantage in improving CTCL patient outcomes.
- Safety and Tolerability: HyBryte™ demonstrated good safety and tolerability, particularly when compared to traditional therapies, as its non-mutagenic mechanism and non-carcinogenic light source make it a safer alternative, reducing the risk of side effects for patients.
- Future Research Directions: Soligenix plans to complete an interim analysis of the FLASH2 study in Q2 2026, which will further validate the efficacy of HyBryte™, with expectations to accelerate patient recruitment and drive the drug's market approval process.
See More
Soligenix Publishes Summary of HyBryte™ Clinical Trials
- Clinical Trial Results: Soligenix's summary of HyBryte™ clinical trials reveals significant efficacy in treating cutaneous T-cell lymphoma (CTCL), with 16% of patients achieving at least a 50% reduction in lesions at 8 weeks in the first phase study, compared to only 4% in the placebo group (p=0.04), laying a solid foundation for future market introduction.
- Safety Advantages: HyBryte™ utilizes a non-mutagenic mechanism and a safe visible light source, demonstrating better tolerability compared to traditional treatments like mechlorethamine, and showing excellent efficacy in treating thicker plaque lesions and difficult-to-treat variants, potentially positioning it as a first-line treatment option for CTCL patients.
- Future Research Plans: The ongoing FLASH2 Phase 3 study is expected to complete its interim analysis in Q2 2026, aiming to further validate the efficacy and safety of HyBryte™, and if successful, will support FDA and EMA marketing approvals, accelerating the product's commercialization process.
- Market Potential: With approximately 69,000 CTCL patients in the U.S. and Europe and about 7,000 new cases annually, the successful development of HyBryte™ could not only meet this unmet medical need but also generate substantial market revenue for Soligenix.
See More
Soligenix Receives PIM Designation for SGX945 in the UK
- PIM Designation Achieved: Soligenix's SGX945 (dusquetide) has received Promising Innovative Medicine (PIM) designation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA), marking a significant advancement in its treatment for Behçet's Disease and potentially accelerating access through the Early Access to Medicines Scheme (EAMS).
- Clinical Data Validation: The MHRA's recognition of dusquetide's compliance with PIM criteria is based on Phase 2 clinical trial data, indicating its potential to provide earlier treatment options for patients, thereby improving their quality of life and addressing unmet medical needs.
- Significant Efficacy: SGX945 demonstrated a 40% improvement compared to placebo after four weeks of treatment, surpassing apremilast's 37% improvement, highlighting its competitive edge in clinical applications and likely attracting increased investor interest.
- Strong IP Position: Soligenix holds robust intellectual property rights in its IDR technology platform, including patents for the composition of dusquetide, which provides legal protection for future market commercialization and enhances the company's competitiveness in the biopharmaceutical sector.
See More
Soligenix Receives UK PIM Designation for SGX945
- PIM Designation Achieved: Soligenix's SGX945 (dusquetide) has received Promising Innovative Medicine (PIM) designation from the UK's MHRA, marking a significant advancement in treating Behçet's Disease and providing patients with earlier access to groundbreaking therapies.
- Clinical Data Support: Based on Phase 2 clinical data, dusquetide is expected to offer significant advantages in treating Behçet's Disease, potentially improving patients' quality of life and alleviating symptoms effectively.
- Substantial Market Potential: With over 1 million patients worldwide suffering from Behçet's Disease, the successful commercialization of SGX945 could fill a critical market gap, addressing the urgent need for effective treatments and potentially generating significant revenue.
- Safety Validation: In a Phase 1 study involving 84 healthy volunteers, SGX945 demonstrated excellent safety and tolerability, with significantly reduced side effects compared to existing treatments, thereby enhancing its competitive position in the market.
See More
Soligenix Receives Positive EMA Orphan Drug Recommendation
- Orphan Drug Qualification: Soligenix announced that its SGX945 (active ingredient dusquetide) received a positive recommendation from the EMA Committee for Orphan Medicinal Products, marking a significant advancement in treating Behçet's Disease and expected to provide a 10-year marketing exclusivity period, enhancing its competitive edge in the rare disease sector.
- Clinical Trial Results: In the Phase 2a clinical trial, SGX945 demonstrated biological efficacy and safety in 8 patients with Behçet's Disease, showing a 40% improvement over the placebo group within 4 weeks, laying a solid foundation for future market approval.
- Significant Market Demand: With approximately 1 million people affected by Behçet's Disease globally, particularly in Turkey and Europe, SGX945 presents substantial market potential to address unmet medical needs, potentially leading to significant revenue growth for the company.
- Intellectual Property Advantage: Soligenix holds a strong intellectual property position in its IDR technology platform, including patents for the composition of dusquetide, which will provide crucial legal protection and competitive advantages in future product development and market commercialization.
See More
Soligenix Receives Positive EMA Orphan Drug Recommendation
- Orphan Drug Qualification: Soligenix announced that its SGX945 (active ingredient dusquetide) received a positive recommendation from the EMA's Committee for Orphan Medicinal Products, marking a significant advancement in the treatment of Behçet's Disease and expected to provide a 10-year market exclusivity period.
- Clinical Trial Results: In the Phase 2a clinical trial, SGX945 demonstrated biological efficacy and safety in 8 patients with Behçet's Disease, showing a 40% improvement compared to the placebo group after 4 weeks, laying the groundwork for future market approval.
- Significant Market Demand: With approximately 1 million people affected by Behçet's Disease globally, particularly in Turkey and Europe, the urgent need for effective treatments highlights the potential market impact of SGX945, significantly enhancing Soligenix's position in the biopharmaceutical sector.
- Intellectual Property Protection: Soligenix holds a strong intellectual property position in its IDR technology platform, including patents for the composition of dusquetide, which will provide crucial support for the company's future product development and market commercialization efforts.
See More
